<DOC>
	<DOCNO>NCT01199302</DOCNO>
	<brief_summary>This study open label extension study 20090072 subject Crohn 's disease . Subjects receive 350 mg AMG 827 intraveneously every 4 week approximately 2 half year . The study evaluate safety efficacy AMG 827 .</brief_summary>
	<brief_title>Safety Study Subjects With Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subject randomize study 20090072 complete week 12 evaluation . Subject complete week 12 evaluation study 20090072 1 year prior plan first visit AMG 827 20100008 . Subject subject 's legally acceptable representative provide informed consent . Subject meet regional recommendation immunization , eg , United States Centers Disease Control Prevention recommendation subject enrol United States . For subject ≥ 3 month week 12 visit 20090072 plan first dose AMG 827 20100008 : If test clinically indicate opinion investigator ( eg , know recent exposure ) , subject negative test hepatitis B , hepatitis C , and/or human immunodeficiency virus ( HIV ) . For female subject ≤ 4 week week 12 visit 20090072 plan first dose AMG 827 20100008 : Subject negative urine pregnancy test baseline prior first dose AMG 827 openlabel extension ( except least 2 year post menopausal surgically sterile ) . For female subject &gt; 4 week week 12 visit 20090072 plan first dose AMG 827 20100008 : Subject negative serum pregnancy test within 28 day initiate AMG 827 negative urine pregnancy test baseline prior first dose AMG 827 openlabel extension ( except least 2 year post menopausal surgically sterile ) . For subject ≥ 3 month week 12 visit 20090072 plan first dose AMG 827 20100008 , clinically indicated opinion investigator ( eg , know recent exposure ) please ass following : If subject enter 20090072 negative purify protein derivative ( PPD ) test : Subject must negative PPD test within 30 day prior plan first dose AMG 827 . Tuberculin skin test consider positive great equal 5 mm induration 4872 hour test place . If subject enter 20090072 positive PPD : Subject must negative Quantiferon test within 30 day prior plan first dose AMG 827 . Subject serious adverse event report study 20090072 consider related investigational product . Subject experienced adverse event laboratory abnormality study 20090072 , opinion investigator , could cause extension treatment detrimental subject , prevent subject complete study , interfere interpretation study result . Subject know sensitivity product administer dosing . Other medical condition Subject currently experience infection Common Terminology Criteria Adverse Events grade 2 ( require oral medication ) high . Subject ineligible infection resolve . Subject serious infection , define require hospitalization intravenous antibiotic , within 8 week first dose AMG 827 20100008 . For subject ≥ 3 month week 12 visit 20090072 plan first dose AMG 827 20100008 : Subject recurrent chronic infection , define ≥ 3 infection require antimicrobial past 12 month prior screen . Subject significant concurrent medical condition , include Type 1 diabetes Uncontrolled type 2 diabetes Moderate severe heart failure ( New York Heart Association class III IV ) Myocardial infarction within last year Current history unstable angina pectoris within last year Uncontrolled hypertension define rest blood pressure ≥ 150/90 mmHg prior first investigational product dose ( confirmed repeat assessment ) Severe chronic pulmonary disease ( eg , require oxygen therapy ) Major chronic inflammatory disease connective tissue disease Crohn 's disease ( eg , systemic lupus erythematosus , rheumatoid arthritis , psoriasis ) Active malignancy , include evidence cutaneous basal squamous cell carcinoma melanoma History cancer ( except successfully treat situ cervical cancer squamous basal cell carcinoma skin ) . Any condition , opinion investigator , might cause study detrimental subject Laboratory abnormality For subject &gt; 4 week week 12 visit 20090072 plan first dose AMG 827 20100008 , subject laboratory abnormality screen , include Elevated aspartate aminotransferase alanine aminotransferase ( &gt; 2x upper limit normal ) Serum direct bilirubin ≥ 1.5x upper limit normal Hemoglobin &lt; 10 g/dL Hemoglobin A1c &gt; 8.0 ( subject type 2 diabetes ) Platelet count &lt; 125,000 /mm3 White blood cell count &lt; 3,000 cells/mm3 Absolute neutrophil count &lt; 2,000/mm3 Creatinine clearance &lt; 50 mL/min ( CockroftGault formula , central lab calculate value provide site ) Any laboratory abnormality , , opinion investigator , could cause extension treatment detrimental subject , prevent subject complete study , interfere interpretation study result Washouts nonpermitted drug Subject use Tysabri ( natalizumab ) subsequent study 20090072 . Subject receive antitumor necrosis factor agent within 8 week prior first dose AMG 827 20100008 . Subject receive commercially available biologic agent ( eg , ustekinumab ) within 12 week prior first dose AMG 827 20100008 . Subject receive investigational agent ( AMG 827 ) , investigational procedure , participate investigational device study subsequent study 20090072 . Subject receive live vaccine within 12 week prior first dose AMG 827 20100008 . Subject receive cyclosporine , mycophenolate mofetil , sirolimus ( rapamycin ) , thalidomide , tacrolimus within 4 week prior first dose AMG 827 20100008 . General Female subject willing use highly effective contraception treatment AMG 827 ( except least 2 year postmenopausal surgically sterile ) . Subject pregnant breast feeding , plan become pregnant enrolled study . Subject kind disorder , opinion investigator , may compromise ability subject give write informed consent and/or comply require study procedure . Subject available protocol require study visit , best subject investigator 's knowledge .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Crohn 's</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>IBD</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>IBS</keyword>
	<keyword>Inflammation</keyword>
	<keyword>bowel</keyword>
	<keyword>colon</keyword>
	<keyword>gastrointestinal</keyword>
</DOC>